Press Releases
FLAMEL APPOINTS MICHAEL MYERS EXECUTIVE VICE PRESIDENT OF SALES,
MARKETING AND BUSINESS DEVELOPMENT
Lyon, France, May 11, 2000 – Flamel Technologies (Nasdaq: FLML)today announced the appointment of Michael Myers, Ph.D., to the position of Executive Vice President responsible for sales, marketing and business development. Dr. Myers has twelve years experience in drug delivery and pharmaceutical research, development and operations, which will contribute to Flamel’s strategic sales and marketing initiatives.
"Dr. Myers is an excellent addition to the Flamel management team," said Dr. Gerard Soula, Flamel’s founder, president and Chief Executive Officer. "As we move to develop new drug delivery projects based on our polymer technology, Dr Myers’ skills and experience will facilitate our growth and development as a biopharmaceutical company and help insure the continued success of our existing Medusa® and Micropump® programmes."
Prior to joining Flamel, Dr. Myers served as president of the pharmaceutical division of Fuisz Technologies, engaged in the development, manufacturing, and commercialization of a wide range of drug delivery. At Fuisz, he led day to day and strategic operations, in addition to business development activities, R&D, manufacturing quality operations and regulatory affairs. Prior to that, Dr Myers held senior R&D positions at Kos Pharmaceuticals and Elan Corporation. He received his Ph.D. in Chemistry from University College Cork, Ireland.
"Flamel’s delivery technologies represent significant advances in this field. I look forward to joining this very successful and highly experienced team and to participating in both the challenges and achievements ahead," commented Dr. Myers on his appointment. "I am pleased with this opportunity to contribute to the success of the company’s exciting products and strategic growth."
Flamel Technologies S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Flamel's Medusa® technology is a controlled-released injectable system based on the company’s proprietary polymers. Medusa is used for delivery of therapeutic proteins, peptids and small molecules. As noted above, Micropump® technology is an oral multiparticulate delivery system utilized for controlled release, taste masking and bioavailability applications. Flamel's expertise in polymer science has also been instrumental in the development of a photochromic eyeglass lens product now marketed by Corning Inc. Additionally, Flamel has developed new herbicide delivery systems now being tested by Monsanto and has patented a biomaterial, ColCysTM .
This document contains a number of matters that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The presentation reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 1999.
